GILEAD SCIENCES, INC. Payments to Acquire Productive Assets
GILEAD SCIENCES, INC. (GILD) reported Payments to Acquire Productive Assets of $825.00 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-25.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireProductiveAssets · last filed 2020-02-25
- GILEAD SCIENCES, INC. payments to acquire productive assets for the quarter ending 2016-12-31 was $169.00M, a 1.81% increase year-over-year.
- GILEAD SCIENCES, INC. payments to acquire productive assets for the quarter ending 2016-09-30 was $198.00M, a 30.77% decline year-over-year.
- GILEAD SCIENCES, INC. payments to acquire productive assets for the quarter ending 2016-06-30 was $204.00M, a 19.30% increase year-over-year.
- GILEAD SCIENCES, INC. payments to acquire productive assets for the quarter ending 2016-03-31 was $177.00M, a 42.74% increase year-over-year.
- GILEAD SCIENCES, INC. payments to acquire productive assets for fiscal 2019 was $825.00M, a 10.71% decline from fiscal 2018.
- GILEAD SCIENCES, INC. payments to acquire productive assets for fiscal 2018 was $924.00M, a 56.61% increase from fiscal 2017.
- GILEAD SCIENCES, INC. payments to acquire productive assets for fiscal 2017 was $590.00M, a 21.12% decline from fiscal 2016.
- GILEAD SCIENCES, INC. payments to acquire productive assets for fiscal 2016 was $748.00M, a 0.13% increase from fiscal 2015.
| Period end | Payments to Acquire Productive Assets 3 month | Payments to Acquire Productive Assets 3 month as first filed | Payments to Acquire Productive Assets 6 month | Payments to Acquire Productive Assets 9 month | Payments to Acquire Productive Assets 9 month as first filed | Payments to Acquire Productive Assets 12 month | Payments to Acquire Productive Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | $825.00M 10-K · filed 2020-02-25 | ||||||
| 2018-12-31 | $924.00M 10-K · filed 2020-02-25 | ||||||
| 2017-12-31 | $590.00M 10-K · filed 2020-02-25 | ||||||
| 2016-12-31 | $169.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $367.00M derived: sum of 2 quarters · filed 2019-02-26 | $571.00M derived: sum of 3 quarters · filed 2019-02-26 | $748.00M 10-K · filed 2019-02-26 | |||
| 2016-09-30 | $198.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $402.00M derived: sum of 2 quarters · filed 2016-11-07 | $579.00M 10-Q · filed 2016-11-07 | $745.00M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2016-06-30 | $204.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | $381.00M 10-Q · filed 2016-08-05 | $547.00M derived: sum of 3 quarters · filed 2018-02-27 | $833.00M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2016-03-31 | $177.00M 10-Q · filed 2016-05-06 | $343.00M derived: sum of 2 quarters · filed 2018-02-27 | $629.00M derived: sum of 3 quarters · filed 2018-02-27 | $800.00M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2015-12-31 | $166.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $452.00M derived: sum of 2 quarters · filed 2018-02-27 | $623.00M derived: sum of 3 quarters · filed 2018-02-27 | $747.00M 10-K · filed 2018-02-27 | |||
| 2015-09-30 | $286.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $457.00M derived: sum of 2 quarters · filed 2016-11-07 | $581.00M 10-Q · filed 2016-11-07 | $748.00M derived: sum of 4 quarters · filed 2017-02-27 | |||
| 2015-06-30 | $171.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | $295.00M 10-Q · filed 2016-08-05 | $462.00M derived: sum of 3 quarters · filed 2017-02-27 | $597.51M derived: sum of 4 quarters · filed 2017-02-27 | |||
| 2015-03-31 | $124.00M 10-Q · filed 2016-05-06 | $291.00M derived: sum of 2 quarters · filed 2017-02-27 | $426.51M derived: sum of 3 quarters · filed 2017-02-27 | $517.00M derived: sum of 4 quarters · filed 2017-02-27 | |||
| 2014-12-31 | $167.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $302.51M derived: sum of 2 quarters · filed 2017-02-27 | $393.00M derived: sum of 3 quarters · filed 2017-02-27 | $557.00M 10-K · filed 2017-02-27 | |||
| 2014-09-30 | $135.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $226.00M derived: sum of 2 quarters · filed 2015-11-04 | $390.00M 10-Q · filed 2015-11-04 | $389.55M 10-Q · filed 2014-11-05 | $458.69M derived: sum of 4 quarters · filed 2016-02-24 | ||
| 2014-06-30 | $90.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-04 | $254.49M 10-Q · filed 2014-08-04 | $323.18M derived: sum of 3 quarters · filed 2016-02-24 | $360.36M derived: sum of 4 quarters · filed 2016-02-24 | |||
| 2014-03-31 | $164.00M 10-Q · filed 2015-05-08 | $163.49M 10-Q · filed 2014-05-07 | $232.69M derived: sum of 2 quarters · filed 2016-02-24 | $269.87M derived: sum of 3 quarters · filed 2016-02-24 | $315.15M derived: sum of 4 quarters · filed 2016-02-24 | ||
| 2013-12-31 | $68.69M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24 | $105.87M derived: sum of 2 quarters · filed 2016-02-24 | $151.15M derived: sum of 3 quarters · filed 2016-02-24 | $190.00M 10-K · filed 2016-02-24 | $190.78M 10-K · filed 2014-02-25 | ||
| 2013-09-30 | $37.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05 | $82.46M derived: sum of 2 quarters · filed 2014-11-05 | $121.31M 10-Q · filed 2014-11-05 | $391.13M derived: sum of 4 quarters · filed 2015-02-25 | |||
| 2013-06-30 | $45.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-04 | $84.13M 10-Q · filed 2014-08-04 | $353.95M derived: sum of 3 quarters · filed 2015-02-25 | $420.54M derived: sum of 4 quarters · filed 2015-02-25 | |||
| 2013-03-31 | $38.85M 10-Q · filed 2014-05-07 | $308.68M derived: sum of 2 quarters · filed 2015-02-25 | $375.26M derived: sum of 3 quarters · filed 2015-02-25 | $412.65M derived: sum of 4 quarters · filed 2015-02-25 | |||
| 2012-12-31 | $269.82M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-25 | $336.41M derived: sum of 2 quarters · filed 2015-02-25 | $373.80M derived: sum of 3 quarters · filed 2015-02-25 | $397.00M 10-K · filed 2015-02-25 | $397.05M 10-K · filed 2013-02-27 | ||
| 2012-09-30 | $66.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-31 | $103.98M derived: sum of 2 quarters · filed 2013-10-31 | $127.17M 10-Q · filed 2013-10-31 | $153.28M derived: sum of 4 quarters · filed 2014-02-25 | |||
| 2012-06-30 | $37.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-01 | $60.59M 10-Q · filed 2013-08-01 | $86.70M derived: sum of 3 quarters · filed 2014-02-25 | $150.99M derived: sum of 4 quarters · filed 2014-02-25 | |||
| 2012-03-31 | $23.20M 10-Q · filed 2013-05-08 | $49.31M derived: sum of 2 quarters · filed 2014-02-25 | $113.60M derived: sum of 3 quarters · filed 2014-02-25 | $140.23M derived: sum of 4 quarters · filed 2014-02-25 | |||
| 2011-12-31 | $26.11M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $90.40M derived: sum of 2 quarters · filed 2014-02-25 | $117.03M derived: sum of 3 quarters · filed 2014-02-25 | $131.90M 10-K · filed 2014-02-25 | |||
| 2011-09-30 | $64.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $90.92M derived: sum of 2 quarters · filed 2012-11-06 | $105.79M 10-Q · filed 2012-11-06 | $129.16M derived: sum of 4 quarters · filed 2013-02-27 | |||
| 2011-06-30 | $26.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-01 | $41.51M 10-Q · filed 2012-08-01 | $64.87M derived: sum of 3 quarters · filed 2013-02-27 | $75.67M derived: sum of 4 quarters · filed 2013-02-27 | |||
| 2011-03-31 | $14.87M 10-Q · filed 2012-05-04 | $38.23M derived: sum of 2 quarters · filed 2013-02-27 | $49.04M derived: sum of 3 quarters · filed 2013-02-27 | $65.09M derived: sum of 4 quarters · filed 2013-02-27 | |||
| 2010-12-31 | $23.36M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | $34.17M derived: sum of 2 quarters · filed 2013-02-27 | $50.22M derived: sum of 3 quarters · filed 2013-02-27 | $61.88M 10-K · filed 2013-02-27 | |||
| 2010-09-30 | $10.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $26.86M derived: sum of 2 quarters · filed 2011-11-04 | $38.52M 10-Q · filed 2011-11-04 | $65.51M derived: sum of 4 quarters · filed 2012-02-23 | |||
| 2010-06-30 | $16.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-05 | $27.72M 10-Q · filed 2011-08-05 | $54.70M derived: sum of 3 quarters · filed 2012-02-23 | $72.83M derived: sum of 4 quarters · filed 2012-02-23 | |||
| 2010-03-31 | $11.67M 10-Q · filed 2011-05-09 | $38.65M derived: sum of 2 quarters · filed 2012-02-23 | $56.78M derived: sum of 3 quarters · filed 2012-02-23 | $77.65M derived: sum of 4 quarters · filed 2012-02-23 | |||
| 2009-12-31 | $26.99M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23 | $45.11M derived: sum of 2 quarters · filed 2012-02-23 | $65.99M derived: sum of 3 quarters · filed 2012-02-23 | $230.06M 10-K · filed 2012-02-23 | |||
| 2009-09-30 | $18.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-08 | $39.00M derived: sum of 2 quarters · filed 2010-11-08 | $203.07M 10-Q · filed 2010-11-08 | $244.73M derived: sum of 4 quarters · filed 2011-02-28 | |||
| 2009-06-30 | $20.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2010-08-09 | $184.94M 10-Q · filed 2010-08-09 | $226.60M derived: sum of 3 quarters · filed 2011-02-28 | $258.00M derived: sum of 4 quarters · filed 2011-02-28 | |||
| 2009-03-31 | $164.07M 10-Q · filed 2010-05-10 | $205.73M derived: sum of 2 quarters · filed 2011-02-28 | $237.13M derived: sum of 3 quarters · filed 2011-02-28 | ||||
| 2008-12-31 | $41.66M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-28 | $73.06M derived: sum of 2 quarters · filed 2011-02-28 | $115.00M 10-K · filed 2011-02-28 | ||||
| 2008-09-30 | $31.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2009-11-05 | $73.34M 10-Q · filed 2009-11-05 | |||||
| 2008-06-30 | $41.95M 10-Q · filed 2009-08-05 | ||||||
| 2007-12-31 | $78.65M 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |